Ishioka Masamichi, Yasui-Furukori Norio, Hashimoto Kojiro, Sugawara Norio
Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan.
Clin Neuropharmacol. 2013 Jul-Aug;36(4):131-2. doi: 10.1097/WNF.0b013e318294799a.
This case report describes a 54-year-old man with bipolar I disorder who was treated with aripiprazole (ARP) and lithium. The patient was admitted to our hospital because of aggravation of depressive symptoms, and treatment with lamotrigine (LTG) was initiated. Two weeks after admission, we discontinued administration of ARP after the appearance of a tremor. Three weeks after discontinuing ARP, the patient developed a high fever, rigidity of the arms, diarrhea, dysphagia, and diaphoresis. We suspected these symptoms were consistent with neuroleptic malignant syndrome and therefore removed the application of LTG. After 2 days, most of the patient's symptoms and blood results had improved, leading us to conclude that the LTG treatment had induced neuroleptic malignant syndrome. Thus, the purpose of this case report was to warn psychiatrists against therapy with LTG, as it may be conducive to neuroleptic malignant syndrome.
本病例报告描述了一名患有双相I型障碍的54岁男性，他接受了阿立哌唑（ARP）和锂盐治疗。患者因抑郁症状加重入院，并开始使用拉莫三嗪（LTG）治疗。入院两周后，患者出现震颤，随后停用了ARP。停用ARP三周后，患者出现高热、手臂僵硬、腹泻、吞咽困难和多汗。我们怀疑这些症状与抗精神病药物恶性综合征相符，因此停用了LTG。两天后，患者的大多数症状和血液检查结果有所改善，这使我们得出结论，LTG治疗诱发了抗精神病药物恶性综合征。因此，本病例报告的目的是提醒精神科医生注意LTG治疗，因为它可能会诱发抗精神病药物恶性综合征。
